220324-83-4

Usage

Class

The compound belongs to the class of imidodicarbonic acid esters.

Physical state

It is a white solid.

Molecular weight

The molecular weight of the compound is 316.44 g/mol.

Uses

The compound is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds.

Stability

The compound is known for its high stability.

Toxicity

The compound has low toxicity.

Applications

The compound has potential applications in the field of medicinal chemistry and drug development due to its unique structural features.

Upstream product

• 51779-32-9 iminodicarboxylic acid di-tert-butyl ester 
• 28188-41-2 m-(bromomethyl)benzonitrile 
• 263159-64-4 2-bromo-3-methyl-benzonitrile 

Downstream Products

• 1234708-04-3 2-(pyridin-2-yl)pyrimidine-5-carboxylic acid 3-[5-(1-hydroxy-1-methylethyl)-1,2,4]oxadiazol-3-yl-benzylamide 
• 1286182-69-1 3-[5-(1-hydroxy-1-methyl-ethyl)-[1,2,4]oxadiazol-3-yl]benzyl-amine hydrochloride 
• 220324-85-6 2-[[3-[(hydroxyamino)iminomethyl]phenyl]methyl]imidodicarbonic acid 1,3-bis(1,1-dimethylethyl) ester 
• 10406-24-3 3-(aminomethyl)benzonitrile 

Relevant academic research and scientific papers

PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS

This invention is directed to a compound of formula (I): wherein R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising the compound, intermediates and processes for making said compounds, and the use of the compound to treat allergi

PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

Selective factor Xa inhibitors

Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.